Pomalidomide (POM) in Combination With Low Dose Dexamethasone (LD-Dex) in Patients With Relapsed or Refractory Multiple Myeloma
Public ClinicalTrials.gov record NCT01632826. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Single-Arm, Open-Label Treatment Use Protocol for Pomalidomide (POM) in Combination With Low Dose Dexamethasone (LD-Dex) in Patients With Relapsed or Refractory Multiple Myeloma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To provide pomalidomide access to relapsed/refractory multiple myeloma subjects with a likelihood of benefit from the pomalidomide treatment while the medication is not commercially available
Study identification
- NCT ID
- NCT01632826
- Recruitment status
- Approved For Marketing
- Study type
- Expanded access
- Phase
- Not listed
- Enrollment
- Not listed
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Not listed
- Primary completion
- Not listed
- Completion
- Not listed
- Last update posted
- Nov 12, 2019
United States locations
- U.S. sites
- 25
- U.S. states
- 20
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Celgene Study Site | Duarte | California | 91010 | — |
| Celgene Study Site | Greenbrae | California | 94904 | — |
| Celgene Study Site | Los Angeles | California | 90048 | — |
| Celgene Study Site | Denver | Colorado | 80218 | — |
| Celgene Study Site | West Palm Beach | Florida | 33401 | — |
| Celgene Study Site | Marietta | Georgia | 30060 | — |
| Celgene Study Site | Peoria | Illinois | 61615 | — |
| Celgene Study Site | Indianapolis | Indiana | 46202 | — |
| Celgene Study Site | Iowa City | Iowa | 52242 | — |
| Celgene Study Site | Baltimore | Maryland | 21215 | — |
| Celgene Study Site | Hyannis | Massachusetts | 02601 | — |
| Celgene Study Site | St Louis | Missouri | 63110 | — |
| Celgene Study Site | Omaha | Nebraska | 68198 | — |
| Celgene Study Site | Hackensack | New Jersey | 07601 | — |
| Celgene Study Site | New York | New York | 10016 | — |
| Celgene Study Site | New York | New York | 10029 | — |
| Celgene Study Site | Philadelphia | Pennsylvania | 19107 | — |
| Celgene Study Site | Sellersville | Pennsylvania | 18960 | — |
| Celgene Study Site | Greenville | South Carolina | 29615 | — |
| Celgene Study Site | Sioux Falls | South Dakota | 57105 | — |
| Celgene Study Site | Dallas | Texas | 75390 | — |
| Celgene Study Site | Houston | Texas | 77030 | — |
| Celgene Study Site | Salt Lake City | Utah | 84106 | — |
| Celgene Study Site | Morgantown | West Virginia | 26506 | — |
| Celgene Study Site | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 17 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01632826, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 12, 2019 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01632826 live on ClinicalTrials.gov.